PRINCIPAL FINANCIAL GROUP INC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 114 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.

Quarter-by-quarter ownership
PRINCIPAL FINANCIAL GROUP INC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q1 2024$131,931
-28.4%
14,708
-10.3%
0.00%
Q4 2023$184,223
+14.5%
16,390
-12.1%
0.00%
Q3 2023$160,838
-7.9%
18,637
+10.5%
0.00%
Q2 2023$174,636
-7.7%
16,873
-3.3%
0.00%
Q1 2023$189,256
-9.1%
17,443
-6.0%
0.00%
Q4 2022$208,187
+15.7%
18,555
+4.7%
0.00%
Q3 2022$180,000
+12.5%
17,726
+0.3%
0.00%
Q2 2022$160,000
+58.4%
17,674
+67.9%
0.00%
Q1 2022$101,000
-45.1%
10,525
-57.6%
0.00%
Q3 2021$184,000
-14.8%
24,799
+67.0%
0.00%
Q2 2021$216,000
-25.0%
14,850
+5.2%
0.00%
Q1 2021$288,000
-31.8%
14,110
-40.7%
0.00%
Q4 2020$422,000
+146.8%
23,776
+105.8%
0.00%
Q3 2020$171,000
-32.9%
11,554
-4.7%
0.00%
Q2 2020$255,000
+27.5%
12,126
+40.3%
0.00%
Q1 2020$200,000
-6.5%
8,640
+4.5%
0.00%
Q4 2019$214,000
+5.9%
8,267
+4.6%
0.00%
Q4 2018$202,000
-57.7%
7,907
-46.0%
0.00%
Q3 2018$478,000
+103.4%
14,632
+51.3%
0.00%
Q1 2018$235,000
-4.5%
9,674
+9.9%
0.00%
Q4 2017$246,000
-16.3%
8,806
+2.7%
0.00%
Q3 2017$294,000
-48.5%
8,572
-40.2%
0.00%
-100.0%
Q2 2017$571,000
+36.0%
14,329
+25.7%
0.00%0.0%
Q1 2017$420,00011,3980.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q1 2021
NameSharesValueWeighting ↓
Chescapmanager LLC 1,157,718$17,117,0002.77%
Baupost Group 8,735,168$129,149,0001.40%
Orbimed Advisors 6,219,110$91,950,0001.16%
Rubric Capital Management LP 550,747$8,143,0000.76%
Cormorant Asset Management, LP 650,072$9,611,0000.37%
Rock Springs Capital Management LP 824,018$12,183,0000.31%
Virtus ETF Advisers LLC 23,148$342,0000.18%
Tekla Capital Management LLC 298,470$4,413,0000.16%
PEREGRINE CAPITAL MANAGEMENT LLC 412,594$6,100,0000.16%
NJ State Employees Deferred Compensation Plan 38,142$564,0000.10%
View complete list of THERAVANCE BIOPHARMA INC shareholders